

QUARTERLY STATEMENT

OF THE

Athene Annuity & Life Assurance Company

TO THE

Insurance Department

OF THE

STATE OF

**FOR THE QUARTER ENDED
SEPTEMBER 30, 2022**

LIFE, ACCIDENT AND HEALTH

FRATERNAL BENEFIT SOCIETIES

2022

STATEMENT AS OF SEPTEMBER 30, 2022 OF THE Athene Annuity & Life Assurance Company

ASSETS

	Current Statement Date			4 December 31 Prior Year Net Admitted Assets
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	
1. Bonds	22,697,142,235		22,697,142,235	22,827,038,704
2. Stocks:				
2.1 Preferred stocks	315,757,895		315,757,895	268,908,861
2.2 Common stocks	2,251,389,214	38,245	2,251,350,969	1,305,010,889
3. Mortgage loans on real estate:				
3.1 First liens	4,004,950,463		4,004,950,463	4,393,822,811
3.2 Other than first liens.....	288,803,711		288,803,711	390,498,772
4. Real estate:				
4.1 Properties occupied by the company (less \$ encumbrances)				
4.2 Properties held for the production of income (less \$ encumbrances)				
4.3 Properties held for sale (less \$ encumbrances)				
5. Cash (\$1,383,459,278), cash equivalents (\$) and short-term investments (\$50,615,247)	1,434,074,525		1,434,074,525	791,284,624
6. Contract loans (including \$ premium notes)	2,064,185		2,064,185	1,981,412
7. Derivatives	403,683,081		403,683,081	209,298,238
8. Other invested assets	1,027,692,548	1,088,082	1,026,604,466	2,019,938,948
9. Receivables for securities	71,107,873		71,107,873	13,744,812
10. Securities lending reinvested collateral assets				
11. Aggregate write-ins for invested assets	86,460,589		86,460,589	9,597,455
12. Subtotals, cash and invested assets (Lines 1 to 11)	32,583,126,319	1,126,328	32,581,999,991	32,231,125,525
13. Title plants less \$ charged off (for Title insurers only)				
14. Investment income due and accrued	198,642,185	1,318,732	197,323,453	174,621,624
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection				
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums)				
15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$)				
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	81,859,085		81,859,085	83,760,657
16.2 Funds held by or deposited with reinsured companies	2,590,872,004		2,590,872,004	2,490,919,980
16.3 Other amounts receivable under reinsurance contracts	2,105,203,773		2,105,203,773	2,693,583,971
17. Amounts receivable relating to uninsured plans				
18.1 Current federal and foreign income tax recoverable and interest thereon				
18.2 Net deferred tax asset	225,146,502	171,610,246	53,536,256	48,362,083
19. Guaranty funds receivable or on deposit	210,966		210,966	299,455
20. Electronic data processing equipment and software				
21. Furniture and equipment, including health care delivery assets (\$)				
22. Net adjustment in assets and liabilities due to foreign exchange rates				
23. Receivables from parent, subsidiaries and affiliates	425,183,262		425,183,262	175,835,334
24. Health care (\$) and other amounts receivable	3,926,006		3,926,006	4,515,331
25. Aggregate write-ins for other than invested assets	21,003,213	19,994,001	1,009,212	954,045
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	38,235,173,314	194,049,307	38,041,124,008	37,903,978,004
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts	12,992,180		12,992,180	17,777,982
28. Total (Lines 26 and 27)	38,248,165,494	194,049,307	38,054,116,188	37,921,755,987
DETAILS OF WRITE-INS				
1101. Derivative collateral asset	86,460,589		86,460,589	9,597,455
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page				
1199. Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	86,460,589		86,460,589	9,597,455
2501. Miscellaneous assets	21,003,213	19,994,001	1,009,212	954,045
2502.				
2503.				
2598. Summary of remaining write-ins for Line 25 from overflow page				
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	21,003,213	19,994,001	1,009,212	954,045

STATEMENT AS OF SEPTEMBER 30, 2022 OF THE Athene Annuity & Life Assurance Company

LIABILITIES, SURPLUS AND OTHER FUNDS

	1 Current Statement Date	2 December 31 Prior Year
1. Aggregate reserve for life contracts \$ 25,153,046,210 less \$ included in Line 6.3 (including \$ 18,299,485,455 Modco Reserve)	25,153,046,210	24,433,619,871
2. Aggregate reserve for accident and health contracts (including \$ Modco Reserve)		
3. Liability for deposit-type contracts (including \$ 80,793,402 Modco Reserve)	398,098,869	452,929,493
4. Contract claims:		
4.1 Life	122,155,022	68,446,062
4.2 Accident and health		
5. Policyholders' dividends/refunds to members \$ and coupons \$ due and unpaid		
6. Provision for policyholders' dividends, refunds to members and coupons payable in following calendar year - estimated amounts:		
6.1 Policyholders' dividends and refunds to members apportioned for payment (including \$ Modco)	30,901	30,901
6.2 Policyholders' dividends and refunds to members not yet apportioned (including \$ Modco)		
6.3 Coupons and similar benefits (including \$ Modco)		
7. Amount provisionally held for deferred dividend policies not included in Line 6		
8. Premiums and annuity considerations for life and accident and health contracts received in advance less \$ discount; including \$ accident and health premiums		
9. Contract liabilities not included elsewhere:		
9.1 Surrender values on canceled contracts		
9.2 Provision for experience rating refunds, including the liability of \$ accident and health experience rating refunds of which \$ is for medical loss ratio rebate per the Public Health Service Act		
9.3 Other amounts payable on reinsurance, including \$ 75,494,848 assumed and \$ 1,915,554,366 ceded	1,991,049,214	1,996,937,529
9.4 Interest Maintenance Reserve	62,596,105	58,689,555
10. Commissions to agents due or accrued-life and annuity contracts \$ 113,447, accident and health \$ 245,461 and deposit-type contract funds \$	358,908	437,670
11. Commissions and expense allowances payable on reinsurance assumed	4,512,036	14,096,457
12. General expenses due or accrued	2,083,057	1,017,695
13. Transfers to Separate Accounts due or accrued (net) (including \$ (51) accrued for expense allowances recognized in reserves, net of reinsured allowances)	(51)	30,550
14. Taxes, licenses and fees due or accrued, excluding federal income taxes	63,100	68,886
15.1 Current federal and foreign income taxes, including \$ 18,477,453 on realized capital gains (losses)	74,830,085	45,923,926
15.2 Net deferred tax liability		
16. Unearned investment income	1,528,363	1,654,944
17. Amounts withheld or retained by reporting entity as agent or trustee	152,841	143,550
18. Amounts held for agents' account, including \$ agents' credit balances		
19. Remittances and items not allocated	4,095,422	14,335,214
20. Net adjustment in assets and liabilities due to foreign exchange rates		
21. Liability for benefits for employees and agents if not included above		
22. Borrowed money \$ and interest thereon \$		
23. Dividends to stockholders declared and unpaid		
24. Miscellaneous liabilities:		
24.01 Asset valuation reserve	123,641,399	459,746,049
24.02 Reinsurance in unauthorized and certified (\$) companies		
24.03 Funds held under reinsurance treaties with unauthorized and certified (\$) reinsurers	5,844,571,410	8,223,547,365
24.04 Payable to parent, subsidiaries and affiliates	432,669,111	184,119,771
24.05 Drafts outstanding		
24.06 Liability for amounts held under uninsured plans		
24.07 Funds held under coinsurance		
24.08 Derivatives	264,093,384	57,479,278
24.09 Payable for securities	27,817,708	28,520,247
24.10 Payable for securities lending		
24.11 Capital notes \$ and interest thereon \$		
25. Aggregate write-ins for liabilities	1,094,809,747	257,684,919
26. Total liabilities excluding Separate Accounts business (Lines 1 to 25)	35,602,202,839	36,299,459,930
27. From Separate Accounts Statement	12,992,180	17,777,982
28. Total liabilities (Lines 26 and 27)	35,615,195,019	36,317,237,912
29. Common capital stock	2,500,000	2,500,000
30. Preferred capital stock		
31. Aggregate write-ins for other than special surplus funds		
32. Surplus notes		
33. Gross paid in and contributed surplus	2,824,586,956	1,926,506,958
34. Aggregate write-ins for special surplus funds		
35. Unassigned funds (surplus)	(388,165,788)	(324,488,883)
36. Less treasury stock, at cost:		
36.1 shares common (value included in Line 29 \$)		
36.2 shares preferred (value included in Line 30 \$)		
37. Surplus (Total Lines 31+32+33+34+35-36) (including \$ in Separate Accounts Statement)	2,436,421,169	1,602,018,076
38. Totals of Lines 29, 30 and 37	2,438,921,169	1,604,518,076
39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3)	38,054,116,188	37,921,755,987
DETAILS OF WRITE-INS		
2501. Repurchase agreement liability	728,383,200	
2502. Derivative collateral liability	300,252,000	194,816,000
2503. Amount due reinsurers	39,054,720	25,539,205
2598. Summary of remaining write-ins for Line 25 from overflow page	27,119,827	37,329,714
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	1,094,809,747	257,684,919
3101.		
3102.		
3103.		
3198. Summary of remaining write-ins for Line 31 from overflow page		
3199. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above)		
3401.		
3402.		
3403.		
3498. Summary of remaining write-ins for Line 34 from overflow page		
3499. Totals (Lines 3401 through 3403 plus 3498)(Line 34 above)		

SUMMARY OF OPERATIONS

	1 Current Year To Date	2 Prior Year To Date	3 Prior Year Ended December 31
1. Premiums and annuity considerations for life and accident and health contracts	357,834,478	566,337,348	839,575,769
2. Considerations for supplementary contracts with life contingencies	34,922,853	46,203,264	60,597,275
3. Net investment income	865,077,966	847,847,803	1,131,187,300
4. Amortization of Interest Maintenance Reserve (IMR)	20,314,257	31,899,484	61,037,618
5. Separate Accounts net gain from operations excluding unrealized gains or losses			
6. Commissions and expense allowances on reinsurance ceded	98,096,150	260,629,877	375,848,728
7. Reserve adjustments on reinsurance ceded	(284,218,533)	963,600,426	1,655,372,766
8. Miscellaneous Income:			
8.1 Income from fees associated with investment management, administration and contract guarantees from Separate Accounts	347,499	359,443	447,755
8.2 Charges and fees for deposit-type contracts			
8.3 Aggregate write-ins for miscellaneous income	77,464,491	80,044,629	115,844,345
9. Totals (Lines 1 to 8.3)	1,169,839,161	2,796,922,274	4,239,911,555
10. Death benefits	(65,105)	958,408	1,215,761
11. Matured endowments (excluding guaranteed annual pure endowments)	32,917	125,376	
12. Annuity benefits	146,018,029	112,614,781	145,975,154
13. Disability benefits and benefits under accident and health contracts			
14. Coupons, guaranteed annual pure endowments and similar benefits			
15. Surrender benefits and withdrawals for life contracts	368,346,352	378,507,041	499,794,814
16. Group conversions			
17. Interest and adjustments on contract or deposit-type contract funds	12,629,713	11,187,579	19,959,582
18. Payments on supplementary contracts with life contingencies	12,834,111	13,134,219	17,613,938
19. Increase in aggregate reserves for life and accident and health contracts	719,426,339	2,020,350,523	3,126,704,509
20. Totals (Lines 10 to 19)	1,259,222,356	2,536,877,927	3,811,263,758
21. Commissions on premiums, annuity considerations, and deposit-type contract funds (direct business only)	1,461,639	1,760,010	2,313,833
22. Commissions and expense allowances on reinsurance assumed	111,421,473	305,576,690	440,433,784
23. General insurance expenses and fraternal expenses	20,008,343	19,606,813	26,645,208
24. Insurance taxes, licenses and fees, excluding federal income taxes	2,282,776	646,106	543,637
25. Increase in loading on deferred and uncollected premiums			
26. Net transfers to or (from) Separate Accounts net of reinsurance	(441,389)	(617,243)	(835,755)
27. Aggregate write-ins for deductions	25,764,916	135,619,472	169,089,827
28. Totals (Lines 20 to 27)	1,419,720,114	2,999,469,775	4,449,454,292
29. Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus Line 28)	(249,880,953)	(202,547,500)	(209,542,737)
30. Dividends to policyholders and refunds to members	18,856	22,504	28,183
31. Net gain from operations after dividends to policyholders, refunds to members and before federal income taxes (Line 29 minus Line 30)	(249,899,809)	(202,570,005)	(209,570,921)
32. Federal and foreign income taxes incurred (excluding tax on capital gains)	56,352,632	(10,763,845)	(30,806,232)
33. Net gain from operations after dividends to policyholders, refunds to members and federal income taxes and before realized capital gains or (losses) (Line 31 minus Line 32)	(306,252,441)	(191,806,160)	(178,764,688)
34. Net realized capital gains (losses) (excluding gains (losses) transferred to the IMR) less capital gains tax of \$ 75,395 (excluding taxes of \$ 21,055,532 transferred to the IMR)	318,607,916	159,565,695	108,518,835
35. Net income (Line 33 plus Line 34)	12,355,476	(32,240,465)	(70,245,853)
CAPITAL AND SURPLUS ACCOUNT			
36. Capital and surplus, December 31, prior year	1,604,518,076	1,699,905,341	1,699,905,341
37. Net income (Line 35)	12,355,476	(32,240,465)	(70,245,853)
38. Change in net unrealized capital gains (losses) less capital gains tax of \$ (141,390,625)	(222,556,840)	(217,482,737)	(539,951,505)
39. Change in net unrealized foreign exchange capital gain (loss)	(136,122,918)	(546,005)	(49,409,358)
40. Change in net deferred income tax	(62,163,152)	11,112,743	52,636,812
41. Change in nonadmitted assets	(74,307,514)	(22,694,450)	(95,496,942)
42. Change in liability for reinsurance in unauthorized and certified companies			
43. Change in reserve on account of change in valuation basis, (increase) or decrease			
44. Change in asset valuation reserve	336,104,650	27,201,849	51,958,610
45. Change in treasury stock			
46. Surplus (contributed to) withdrawn from Separate Accounts during period			
47. Other changes in surplus in Separate Accounts Statement			
48. Change in surplus notes			
49. Cumulative effect of changes in accounting principles			
50. Capital changes:			
50.1 Paid in			
50.2 Transferred from surplus (Stock Dividend)			
50.3 Transferred to surplus			
51. Surplus adjustment:			
51.1 Paid in	898,079,998	42,768,363	524,417,529
51.2 Transferred to capital (Stock Dividend)			
51.3 Transferred from capital			
51.4 Change in surplus as a result of reinsurance	83,013,393	29,615,885	30,703,440
52. Dividends to stockholders			
53. Aggregate write-ins for gains and losses in surplus			
54. Net change in capital and surplus for the year (Lines 37 through 53)	834,403,093	(162,264,816)	(95,387,266)
55. Capital and surplus, as of statement date (Lines 36 + 54)	2,438,921,169	1,537,640,525	1,604,518,076
DETAILS OF WRITE-INS			
08.301. Funds withheld adjustment - assumed	77,428,257	79,437,517	115,195,459
08.302. Miscellaneous income	36,234	607,112	648,885
08.303.			
08.398. Summary of remaining write-ins for Line 8.3 from overflow page			
08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above)	77,464,491	80,044,629	115,844,345
2701. Funds withheld adjustment - ceded	97,878,038	205,473,163	275,604,318
2702. Transfer to IMR - ceded	(57,149,991)	(53,928,596)	(94,604,021)
2703. Reserve adjustments on reinsurance assumed	(17,287,481)	(6,548,116)	(9,551,183)
2798. Summary of remaining write-ins for Line 27 from overflow page	2,324,350	(9,376,979)	(2,359,287)
2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above)	25,764,916	135,619,472	169,089,827
5301.			
5302.			
5303.			
5398. Summary of remaining write-ins for Line 53 from overflow page			
5399. Totals (Lines 5301 through 5303 plus 5398)(Line 53 above)			

STATEMENT AS OF SEPTEMBER 30, 2022 OF THE Athene Annuity & Life Assurance Company

CASH FLOW

	1 Current Year To Date	2 Prior Year To Date	3 Prior Year Ended December 31
Cash from Operations			
1. Premiums collected net of reinsurance	392,757,331	612,540,612	900,173,044
2. Net investment income	821,338,113	801,909,624	1,085,077,787
3. Miscellaneous income	95,602,048	258,677,884	373,029,481
4. Total (Lines 1 to 3)	1,309,697,491	1,673,128,120	2,358,280,312
5. Benefit and loss related payments	(147,269,791)	(176,203,541)	(760,149,236)
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	(410,788)	(589,469)	(843,823)
7. Commissions, expenses paid and aggregate write-ins for deductions	139,252,113	329,663,401	470,780,793
8. Dividends paid to policyholders	18,856	22,504	30,819
9. Federal and foreign income taxes paid (recovered) net of \$ 51,172,854 tax on capital gains (losses)	48,577,400	23,461,922	41,853,010
10. Total (Lines 5 through 9)	40,167,789	176,354,818	(248,328,437)
11. Net cash from operations (Line 4 minus Line 10)	1,269,529,702	1,496,773,303	2,606,608,749
Cash from Investments			
12. Proceeds from investments sold, matured or repaid:			
12.1 Bonds	2,711,672,840	4,029,410,890	6,105,576,764
12.2 Stocks	52,220,732	25,644,373	22,748,954
12.3 Mortgage loans	922,822,027	537,407,649	800,204,443
12.4 Real estate			
12.5 Other invested assets	2,470,546,431	650,753,495	1,117,780,194
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	3,106,155	(1,602,649)	(20,583,592)
12.7 Miscellaneous proceeds	104,819,748	251,964,364	189,165,390
12.8 Total investment proceeds (Lines 12.1 to 12.7)	6,265,187,932	5,493,578,122	8,214,892,153
13. Cost of investments acquired (long-term only):			
13.1 Bonds	3,141,467,510	5,778,221,037	8,842,742,310
13.2 Stocks	19,177,164	71,357,597	405,169,620
13.3 Mortgage loans	611,305,437	1,275,488,809	1,727,644,273
13.4 Real estate			899,616
13.5 Other invested assets	1,376,911,509	693,783,721	1,111,436,865
13.6 Miscellaneous applications	134,928,733	16,287,363	716,312
13.7 Total investments acquired (Lines 13.1 to 13.6)	5,283,790,352	7,835,138,527	12,088,608,997
14. Net increase (or decrease) in contract loans and premium notes	82,773	(4,601)	(142,441)
15. Net cash from investments (Line 12.8 minus Line 13.7 and Line 14)	981,314,807	(2,341,555,804)	(3,873,574,403)
Cash from Financing and Miscellaneous Sources			
16. Cash provided (applied):			
16.1 Surplus notes, capital notes			
16.2 Capital and paid in surplus, less treasury stock			300,000,000
16.3 Borrowed funds			
16.4 Net deposits on deposit-type contracts and other insurance liabilities	(54,830,624)	58,495,805	75,690,694
16.5 Dividends to stockholders			
16.6 Other cash provided (applied)	(1,553,223,984)	44,031,945	339,093,358
17. Net cash from financing and miscellaneous sources (Line 16.1 through Line 16.4 minus Line 16.5 plus Line 16.6)	(1,608,054,608)	102,527,750	714,784,052
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS			
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	642,789,901	(742,254,751)	(552,181,602)
19. Cash, cash equivalents and short-term investments:			
19.1 Beginning of year	791,284,624	1,343,466,227	1,343,466,227
19.2 End of period (Line 18 plus Line 19.1)	1,434,074,525	601,211,476	791,284,624

Note: Supplemental disclosures of cash flow information for non-cash transactions:

20.0001. Security exchanges and asset in kind trades - bond proceeds (investing)	793,798,923	446,221,996	798,668,886
20.0002. Security exchanges and asset in kind trades - bonds acquired (investing)	(793,798,923)	(446,221,996)	(798,668,886)
20.0003. Security exchanges and asset in kind trades - other invested asset proceeds (investing)	84,730,324	23,185,108	23,685,108
20.0004. Security exchanges and asset in kind trades - other invested asset acquired (investing)	(84,730,324)	(23,185,108)	(23,685,108)
20.0005. Reinsurance activity settled in assets in kind (operating)	132,024,576	174,219,244	185,754,428
20.0006. Ceded reinsurance activity settled in bonds (investing)	(132,024,576)	(176,222,189)	(186,744,428)
20.0007. Capital contribution of stock compensation expense (financing)	22,785,549	15,553,032	22,202,198
20.0008. Capital contribution of stock compensation expense (investing)	(18,348,310)	(10,897,712)	(15,707,346)
20.0009. Capital contribution of stock compensation expense (operating)	(4,437,239)	(4,655,320)	(6,494,852)
20.0010. Capital contribution - non-cash (financing)	450,294,449	27,215,331	27,215,331

STATEMENT AS OF SEPTEMBER 30, 2022 OF THE Athene Annuity & Life Assurance Company

Note: Supplemental disclosures of cash flow information for non-cash transactions:

20.0011. Capital contribution - non-cash (investing)	(450,294,449)	(27,215,331)	(27,215,331)
20.0012. Asset transfer bonds to stocks - proceeds (investing)	141,165,696		5,000,000
20.0013. Asset transfer bonds to stocks - acquired (investing)	(141,165,696)		(5,000,000)
20.0014. Asset transfer mortgage to other invested assets - proceeds (investing)	696,183		
20.0015. Asset transfer mortgage to other invested assets - acquired (investing)	(696,183)		
20.0016. Asset transfer stocks to bonds - proceeds (investing)	21,527,835		
20.0017. Asset transfer stocks to bonds - acquired (investing)	(21,527,835)		
20.0018. Assumed reinsurance activity settled in bonds (investing)		990,000	990,000
20.0019. Ceded reinsurance activity settled in other invested assets (investing)		1,012,945	
20.0020. Asset transfer bonds to other invested assets - proceeds (investing)			69,200
20.0021. Asset transfer bonds to other invested assets - acquired (investing)			(69,200)

Notes to the Financial Statements

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of **Athene Annuity & Life Assurance Company** (the Company) have been prepared in conformity with the accounting practices prescribed or permitted by the National Association of Insurance Commissioners (NAIC) and the State of Delaware.

The Department of Insurance of the State of Delaware (the Department) recognizes only statutory accounting practices prescribed or permitted by the State of Delaware for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Delaware Insurance Law. The NAIC's *Accounting Practices & Procedures Manual* (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Delaware. The Department has the right to permit other specific practices that deviate from prescribed practices.

Effective December 31, 2014, the Company received a permitted practice to use the standard scenario to determine the reserve on its variable annuity policies and thus did not calculate the stochastic scenario reserve as required under Actuarial Guideline 43. The Company does not believe this difference in valuation method has any impact on the calculated reserves. Therefore, the Company's net income and statutory surplus are not affected as a result of this permitted practice.

A reconciliation of the Company's net income and statutory surplus between practices prescribed by the State of Delaware and NAIC SAP is shown below:

	SSAP #	F/S Page	F/S Line #	09/30/2022	12/31/2021
Net Income					
(1) State basis (Page 4, Line 35, Columns 1 & 3)	XXX	XXX	XXX	\$ 12,355,476	\$ (70,245,853)
(2) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(3) State permitted practices that are an increase / (decrease) from NAIC SAP:					
Standard scenario on variable annuities	51	3	1		
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	<u>\$ 12,355,476</u>	<u>\$ (70,245,853)</u>
Surplus					
(5) State basis (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	XXX	\$ 2,438,921,169	\$ 1,604,518,076
(6) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(7) State permitted practices that are an increase / (decrease) from NAIC SAP:					
Standard scenario on variable annuities	51	3	1		
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	<u>\$ 2,438,921,169</u>	<u>\$ 1,604,518,076</u>

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC SAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results may differ from the estimates used in preparing the financial statements.

C. Accounting Policy

- (1) Short-term investments - No Significant Changes
- (2) Bonds, other than loan-backed and structured securities, are stated at amortized cost or fair value based on their rating by the NAIC. Bonds held at amortized cost are amortized using the scientific interest method on a yield-to-worst basis.
- (3) Common stocks - No Significant Changes
- (4) Preferred stocks - No Significant Changes
- (5) Mortgage loans - No Significant Changes
- (6) Loan-backed and structured securities are stated at amortized cost or fair market value based on their rating by the NAIC. Changes to estimated cash flows on the securities are accounted for retrospectively for securities that are highly rated at the time of purchase and in which the security cannot be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. The prospective method is used for those securities where an other than temporary impairment has been taken, the security is not highly rated at the time of purchase, securities where receipt of all contractual principal cash flows is not expected, or those securities that can be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. Loan-backed and structured securities stated at amortized cost are amortized or accreted using the scientific interest method.
- (7) Investments in subsidiaries, controlled and affiliated entities - No Significant Changes
- (8) Investments in joint ventures, partnerships and limited liability entities - No Significant Changes
- (9) Derivatives - No Significant Changes
- (10) Investment income as a factor in the premium deficiency calculation - No Significant Changes
- (11) Liabilities for losses and loss/claim adjustment expenses - No Significant Changes
- (12) Changes in capitalization policy - No Significant Changes
- (13) Pharmaceutical rebate receivables - No Significant Changes

D. Going Concern

Management's assessment of the relevant conditions through November 14, 2022 does not give rise to substantial doubt of the Company's ability to continue as a going concern.

Notes to the Financial Statements

2. Accounting Changes and Corrections of Errors - None

3. Business Combinations and Goodwill - None

4. Discontinued Operations - None

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans - No Significant Changes

B. Debt Restructuring - None

C. Reverse Mortgages - None

D. Loan-Backed Securities

(1) Prepayment assumptions for loan-backed bonds and structured securities were obtained from broker dealer survey values or internal estimates.

(2) Loan-backed and structured securities with a recognized other-than-temporary impairment (OTTI) - None

(3) Securities held that were other-than-temporarily impaired due to the present value of cash flows expected to be collected was less than the amortized cost of securities

(1)	(2)	(3)	(4)	(5)	(6)	(7)
CUSIP	Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	Present Value of Projected Cash Flows	Recognized OTTI	Amortized Cost After OTTI	Fair Value at Time of OTTI	Date of Financial Statement Where Reported
12641TAS5	\$ 6,611,550	\$ 6,465,642	\$ 145,908	\$ 6,465,642	\$ 6,361,021	03/31/2022
41161PVJ9	5,172,738	5,171,535	1,203	5,171,535	1,965,529	03/31/2022
46634FAJ2	723,622	715,326	8,296	715,326	641,750	03/31/2022
59023MAD2	2,933,149	2,929,814	3,334	2,929,814	2,829,037	03/31/2022
86360JAN1	1,367,576	1,179,160	188,416	1,179,160	1,179,160	03/31/2022
1248MBAF2	1,429,678	1,415,436	14,242	1,415,436	1,313,400	06/30/2022
12543WAA6	1,427,832	1,415,094	12,738	1,415,094	1,231,680	06/30/2022
12641TAS5	5,700,292	5,672,653	27,639	5,672,653	5,397,292	06/30/2022
12668BMY6	1,934,315	1,922,212	12,103	1,922,212	1,837,079	06/30/2022
126694NV6	658,011	623,717	34,294	623,717	610,761	06/30/2022
17309VAA1	1,258,381	1,252,677	5,704	1,252,677	1,179,113	06/30/2022
46627MED5	889,021	875,160	13,861	875,160	800,550	06/30/2022
46630RAY7	1,098,430	1,085,276	13,154	1,085,276	990,186	06/30/2022
59020UW27	4,138,335	3,546,276	592,059	3,546,276	3,166,507	06/30/2022
61758VAR8	5,481,427	5,190,457	290,970	5,190,457	4,694,503	06/30/2022
93935HAJ6	2,922,151	2,916,475	5,676	2,916,475	2,772,955	06/30/2022
12641TAS5	5,353,943	5,156,800	197,143	5,156,800	4,758,696	09/30/2022
32053EAA6	532,819	520,382	12,437	520,382	494,433	09/30/2022
61756VAG4	2,348,778	2,347,259	1,519	2,347,259	2,143,184	09/30/2022
126694NV6	569,364	562,069	7,295	562,069	517,692	09/30/2022
25151OLF8	412,066	404,913	7,153	404,913	373,733	09/30/2022
0738794H8	338,522	267,606	70,916	267,606	242,588	09/30/2022
362341FN4	1,709,367	1,686,673	22,694	1,686,673	1,475,782	09/30/2022
Total			\$ 1,688,755			

(4) All impaired securities for which an OTTI has not been recognized in earnings as a realized loss

The following table shows the gross unrealized losses and fair values of loan-backed securities, which have not been impaired to fair value, aggregated by length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2022.

a. The aggregate amount of unrealized losses:

1. Less than 12 months	\$ 905,970,118
2. 12 months or longer	219,587,084

b. The aggregate related fair value of securities with unrealized losses:

1. Less than 12 months	\$ 7,156,016,216
2. 12 months or longer	1,476,751,231

(5) A full analysis of all relevant qualitative considerations was completed in reaching the conclusion that the impairments were not other-than-temporary, including the intent and ability to hold the investment for a period of time sufficient to allow for a recovery in value. Specific events that may influence the operations of the issuer and impaired earnings potential are reviewed in addition to length of time and extent to which the fair value has been less than cost.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions - None

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Taker - Overview of Secured Borrowing Transactions

Notes to the Financial Statements

5. Investments (Continued)

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral

The Company participates in repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company lends bonds and receives cash as collateral. The Company monitors the estimated fair value of the collateral and the securities loaned throughout the duration of the contract and contributes additional collateral as necessary. Securities loaned under these agreements may be sold or re-pledged by the transferee.

(2) Type of repo trades used

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Bilateral (Yes/No).....		YES	YES	
b. Tri-Party (Yes/No).....		NO	NO	

(3) Original (flow) & residual maturity

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Open - No maturity.....	\$.....	\$.....	\$.....	\$.....
2. Overnight.....				
3. 2 days to 1 week.....				-
4. Over 1 week to 1 month.....				-
5. Over 1 month to 3 months.....				
6. Over 3 months to 1 year.....				
7. Over 1 year.....		701,451,300	728,383,200	
b. Ending Balance				
1. Open - No maturity.....	\$.....	\$.....	\$.....	\$.....
2. Overnight.....				
3. 2 days to 1 week.....				
4. Over 1 week to 1 month.....				
5. Over 1 month to 3 months.....				
6. Over 3 months to 1 year.....				
7. Over 1 year.....		701,451,300	728,383,200	

(4) Fair value of securities sold and/or acquired that resulted in default

The Company did not have any securities sold or outstanding for which the repurchase agreement defaulted as of September 30, 2022.

(5) Securities "sold" under repo - secured borrowing

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. BACV.....	XXX	XXX	XXX	\$.....
2. Nonadmitted - Subset of BACV.....	XXX	XXX	XXX	\$.....
3. Fair Value.....	\$.....	\$ 722,701,160	\$ 722,701,160	\$.....
b. Ending Balance				
1. BACV.....	XXX	XXX	XXX	\$.....
2. Nonadmitted - Subset of BACV.....	XXX	XXX	XXX	\$.....
3. Fair Value.....	\$.....	\$ 722,701,160	\$ 692,658,339	\$.....

Notes to the Financial Statements

5. Investments (Continued)

(6) Securities sold under repo - secured borrowing by NAIC designation

Ending Balance	(1) None	(2) NAIC 1	(3) NAIC 2	(4) NAIC 3	(5) NAIC 4	(6) NAIC 5	(7) NAIC 6	(8) Nonadmitted
a. Bonds - BACV	\$	\$ 410,669,590	\$ 471,985,887	\$	\$	\$	\$	\$
b. Bonds - FV		319,847,496	372,810,844					
c. LB & SS - BACV								
d. LB & SS - FV								
e. Preferred stock - BACV								
f. Preferred stock - FV								
g. Common stock								
h. Mortgage loans - BACV								
i. Mortgage loans - FV								
j. Real estate - BACV								
k. Real estate - FV								
l. Derivatives - BACV								
m. Derivatives - FV								
n. Other invested assets - BACV								
o. Other invested assets - FV								
p. Total assets - BACV	\$	\$ 410,669,590	\$ 471,985,887	\$	\$	\$	\$	\$
q. Total assets - FV	\$	\$ 319,847,496	\$ 372,810,844	\$	\$	\$	\$	\$

(7) Collateral received - secured borrowing

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Cash	\$	\$ 701,451,300	\$ 728,383,200	\$
2. Securities (FV)				
b. Ending Balance				
1. Cash	\$	\$ 701,451,300	\$ 728,383,200	\$
2. Securities (FV)				

(8) Cash & non-cash collateral received - secured borrowing by NAIC designation

Ending Balance	(1) None	(2) NAIC 1	(3) NAIC 2	(4) NAIC 3	(5) NAIC 4	(6) NAIC 5	(7) NAIC 6	(8) Does Not Qualify as Admitted
a. Cash	\$ 728,383,200	\$	\$	\$	\$	\$	\$	\$
b. Bonds - FV								
c. LB & SS - FV								
d. Preferred stock - FV								
e. Common stock								
f. Mortgage loans - FV								
g. Real estate - FV								
h. Derivatives - FV								
i. Other Invested Assets - FV								
j. Total collateral assets - FV (sum of a through i)	\$ 728,383,200	\$	\$	\$	\$	\$	\$	\$

(9) Allocation of aggregate collateral by remaining contractual maturity

	Fair Value
a. Overnight and continuous	\$
b. 30 Days or less	
c. 31 to 90 Days	
d. More than 90 days	728,383,200

(10) Allocation of aggregate collateral reinvested by remaining contractual maturity

	Amortized Cost	Fair Value
a. 30 Days or less	\$ 728,383,200	\$ 728,383,200
b. 31 to 60 Days		
c. 61 to 90 Days		
d. 91 to 120 Days		
e. 121 to 180 Days		
f. 181 to 365 Days		
g. 1 to 2 Years		
h. 2 to 3 Years		
i. More than 3 years		

Notes to the Financial Statements

5. Investments (Continued)

(11) Liability to return collateral - secured borrowing (total)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Cash (Collateral - All)	\$	\$ 701,451,300	\$ 728,383,200	\$
2. Securities Collateral (FV)
b. Ending Balance				
1. Cash (Collateral - All)	\$	\$ 701,451,300	\$ 728,383,200	\$
2. Securities Collateral (FV)

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Provider - Overview of Secured Borrowing Transactions

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral

Included in short-term investments are amounts receivable under reverse repurchase agreements, which involves the purchase of investments from a seller with the agreement that the investments will be repurchased by the seller at a specified price, and at a specified date or within a specified period of time. The investments purchased, which represent collateral on a secured lending arrangement, are not reflected in the Company's balance sheets. Instead, the secured lending arrangement is reflected as a short-term investment for the principal amount loaned under the agreement.

(2) Type of repo trades used

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Bilateral (Yes/No)	YES	YES	YES
b. Tri-Party (Yes/No)	NO	NO	NO

(3) Original (flow) & residual maturity

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Open - No maturity	\$	\$	\$	\$
2. Overnight
3. 2 days to 1 week
4. Over 1 week to 1 month
5. Over 1 month to 3 months
6. Over 3 months to 1 year	25,940,247	25,940,247
7. Over 1 year	25,940,247
b. Ending Balance				
1. Open - No maturity	\$	\$	\$	\$
2. Overnight
3. 2 days to 1 week
4. Over 1 week to 1 month
5. Over 1 month to 3 months
6. Over 3 months to 1 year	25,940,247	25,940,247
7. Over 1 year	25,940,247

(4) Fair value of securities sold and/or acquired that resulted in default - None

(5) Fair value of securities acquired under repo - secured borrowing

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount	\$ 25,940,247	\$ 25,940,247	\$ 25,940,247	\$
b. Ending Balance	\$ 25,940,247	\$ 25,940,247	\$ 25,940,247	\$

Notes to the Financial Statements

5. Investments (Continued)

(6) Securities acquired under repo - secured borrowing by NAIC designation

Ending Balance	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
	None	NAIC 1	NAIC 2	NAIC 3	NAIC 4	NAIC 5	NAIC 6	Does Not Qualify as Admitted
a. Bonds - FV	\$	\$	\$ 25,940,247	\$	\$	\$	\$	\$
b. LB & SS - FV								
c. Preferred stock - FV								
d. Common stock								
e. Mortgage loans - FV								
f. Real estate - FV								
g. Derivatives - FV								
h. Other invested assets - FV								
i. Total assets - FV (Sum of a through h)	\$	\$	\$ 25,940,247	\$	\$	\$	\$	\$

(7) Collateral provided - secured borrowing

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Cash	\$ 615,740,809	\$ 615,740,809	\$ 615,740,809	\$
2. Securities (FV)				
3. Securities (BACV)	XXX	XXX	XXX	XXX
4. Nonadmitted Subset (BACV)	XXX	XXX	XXX	XXX
b. Ending Balance				
1. Cash	\$ 615,740,809	\$ 615,740,809	\$ 615,740,809	\$
2. Securities (FV)				
3. Securities (BACV)				
4. Nonadmitted Subset (BACV)				

(8) Allocation of aggregate collateral pledged by remaining contractual maturity - None

(9) Recognized receivable for return of collateral - secured borrowing

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a. Maximum Amount				
1. Cash	\$	\$	\$	\$
2. Securities (FV)	25,940,247	25,940,247	25,940,247	
b. Ending Balance				
1. Cash	\$	\$	\$	\$
2. Securities (FV)	25,940,247	25,940,247	25,940,247	

(10) Recognized liability to return collateral - secured borrowing (total) - None

- H. Repurchase Agreements Transactions Accounted for as a Sale - None
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale - None
- J. Real Estate - None
- K. Low-Income Housing Tax Credits (LIHTC) - None
- L. Restricted Assets - No Significant Changes
- M. Working Capital Finance Investments - None
- N. Offsetting and Netting of Assets and Liabilities - None
- O. 5GI Securities - No Significant Changes
- P. Short Sales - None
- Q. Prepayment Penalty and Acceleration Fees - No Significant Changes
- R. Reporting Entity's Share of Cash Pool by Asset type - None

6. Joint Ventures, Partnerships and Limited Liability Companies - No Significant Changes

7. Investment Income - No Significant Changes

8. Derivative Instruments

A. Derivatives under SSAP No. 86 - Derivatives

- (1) Discussion - No Significant Changes
- (2) Description of objectives - No Significant Changes

Notes to the Financial Statements

8. Derivative Instruments (Continued)

- (3) Description of accounting policies - No Significant Changes
- (4) Derivative contracts with financing premiums - No Significant Changes
- (5) Net gain or loss recognized - No Significant Changes
- (6) Net gain or loss recognized from derivatives no longer qualifying for hedge accounting - No Significant Changes
- (7) Derivatives accounted for as cash flow hedges of a forecasted transaction - No Significant Changes
- (8) Premium Cost for Derivative Contracts - None

B. Derivatives under SSAP No. 108 - Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) - None

9. Income Taxes

In August 2022, the US government enacted legislation commonly known as the Inflation Reduction Act of 2022 (Act). The Act imposes a corporate alternative minimum tax (CAMT) on certain large corporations based on adjusted financial statement income. The CAMT goes into effect for tax years beginning after December 31, 2022. It is unclear how the US Department of Treasury will implement the CAMT through regulation.

The controlled group of corporations of which the reporting entity is a member has not determined as of the reporting date whether they will be liable for CAMT in 2023. The third quarter 2022 financial statements do not include an estimated impact of the CAMT, because a reasonable estimate cannot be made.

- A. Components of the Net Deferred Tax Asset/(Liability) - No Significant Changes
- B. Regarding Deferred Tax Liabilities That Are Not Recognized - No Significant Changes
- C. Major Components of Current Income Taxes Incurred - No Significant Changes
- D. Among the More Significant Book to Tax Adjustments - No Significant Changes
- E. Operating Loss and Tax Credit Carryforwards - No Significant Changes
- F. Consolidated Federal Income Tax Return - No Significant Changes
- G. Federal or Foreign Income Tax Loss Contingencies - No Significant Changes
- H. Repatriation Transition Tax (RTT) - None
- I. Alternative Minimum Tax (AMT) Credit - None

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. On March 8, 2021, Athene Holding Ltd. (AHL), an indirect parent of the Company, entered into an Agreement and Plan of Merger (Merger Agreement), by and among AHL, Apollo Global Management, Inc., a Delaware corporation (AGM), Tango Holdings, Inc., a Delaware corporation and a direct wholly owned subsidiary of AGM (HoldCo), Blue Merger Sub, Ltd., a Bermuda exempted company and a direct wholly owned subsidiary of HoldCo (AHL Merger Sub), and Green Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of HoldCo (AGM Merger Sub). AHL and AGM have agreed, subject to the terms and conditions of the Merger Agreement, to effect an all-stock merger transaction to combine the respective businesses by: (1) AGM merging with AGM Merger Sub, with AGM surviving such merger as a direct wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AHL Merger and, together with the AGM Merger, Mergers), and (3) as of the effective time of the Mergers, changing the name of HoldCo to be Apollo Global Management, Inc. The Mergers closed on January 1, 2022, and AHL became a direct wholly owned subsidiary of AGM. Additionally, following the completion of the Mergers, AUSA contributed to its direct wholly owned subsidiary, AARe, AUSA's ownership in the Company whereas the Company became a direct wholly owned subsidiary of AARe.

Some employees of Athene Employee Services LLC and Athene Annuity and Life Company (AAIA) participate in one or more Share Award Agreements (the Agreements) sponsored by AHL, for which the Company has no legal obligation. Salary expense of Athene Employee Services LLC and AAIA is allocated to the Company through the Shared Services Agreement. Under SSAP No. 104R, *Share-Based Payments*, the stock compensation expense associated with the Agreements that would have been allocated to the Company is required to be recorded as a capital contribution to the reporting entity. The Company has allocated the stock compensation expense associated with the Agreements based on the same methodology as the Shared Services Agreement. In accordance with SSAP No. 104R, the Company incurred expense and recorded a capital contribution under the Agreements totaling \$22.8 million and \$22.2 million for the nine months ended September 30, 2022 and for the year ended December 31, 2021, respectively, which includes amounts contributed by the Company to downstream insurance subsidiaries.

During February 2022, the Company received a \$175.3 million capital contribution from its parent and paid a \$175.3 million capital contribution to its wholly owned subsidiary, AAIA. The capital contribution was accrued at December 31, 2021 as a \$175.0 million receivable from parent with a corresponding increase in gross paid-in and contributed surplus. The contribution to AAIA was accrued at December 31, 2021 as a \$175.0 million payable to subsidiary with a corresponding increase to investment in affiliated common stock. In accordance with SSAP No. 72 *Surplus and Quasi-Reorganizations*, capital contributions receivable that are satisfied with the receipt of cash or marketable securities prior to the filing of the annual statement shall be treated as a Type I subsequent event and considered an admitted asset based on evidence of collection and approval of the domiciliary commissioner.

During August 2022, the Company received a \$450 million capital contribution from its parent, AARe, and paid a \$450 million capital contribution to its wholly owned subsidiary, AAIA. The capital contribution was accrued at June 30, 2022 as a receivable from parent with a corresponding increase in gross paid-in and contributed surplus. The contribution to AAIA was accrued at June 30, 2022 as a payable to subsidiary with a corresponding increase to investment in affiliated common stock. In accordance with SSAP No. 72 *Surplus and Quasi-Reorganizations*, capital contributions receivable that are satisfied with the receipt of cash or marketable securities prior to the filing of the financial statement shall be treated as a Type I subsequent event and considered an admitted asset based on evidence of collection and approval of the domiciliary commissioner.

During November 2022, the Company received a \$425 million capital contribution from its parent, AARe, and paid a \$425 million capital contribution to its wholly owned subsidiary, AAIA. The capital contribution was accrued at September 30, 2022 as a receivable from parent with a corresponding increase in gross paid-in and contributed surplus. The contribution to AAIA was accrued at September 30, 2022 as a payable to subsidiary with a corresponding increase to investment in affiliated common stock. In accordance with SSAP No. 72 *Surplus and Quasi-Reorganizations*, capital contributions receivable that are satisfied with the receipt of cash or marketable securities prior to the filing of the financial statement shall be treated as a Type I subsequent event and considered an admitted asset based on evidence of collection and approval of the domiciliary commissioner.

- B. Detail of Related Party Transactions - No Significant Changes

Notes to the Financial Statements

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties (Continued)

- C. Transactions With Related Party Who Are Not Reported on Schedule Y - No Significant Changes
- D. Amounts Due To or From Related Parties - No Significant Changes
- E. Management Service Contracts and Cost Sharing Arrangements - No Significant Changes
- F. Guarantees or Contingencies - None
- G. Nature of Relationships that Could Affect Operations - No Significant Changes
- H. Amount Deducted for Investment in Upstream Company - None
- I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets - No Significant Changes
- J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies - No Significant Changes
- K. Foreign Subsidiary Value Using CARVM - No Significant Changes
- L. Downstream Holding Company Value Using Look-Through Method - No Significant Changes
- M. All SCA Investments - No Significant Changes
- N. Investment in Insurance SCAs - No Significant Changes
- O. SCA and SSAP No. 48 Entity Loss Tracking - None

11. Debt

- A. Debt, Including Capital Notes - No Significant Changes
- B. FHLB (Federal Home Loan Bank) Agreements

(1)

The Company is a member of the FHLB of Des Moines. Through its membership, the Company is eligible to borrow under variable rate short-term federal fund arrangements to provide additional liquidity. These borrowings are accounted for as borrowed money under SSAP No. 15, *Debt and Holding Company Obligations*. During October 2021, the Company borrowed \$80.0 million with an interest rate of 0.3% under the FHLB short-term arrangement. The borrowing was repaid during December 2021. The Company did not have any outstanding borrowings as of September 30, 2022 or December 31, 2021. The Company incurred no interest expense on short-term borrowings for the nine months ended September 30, 2022, and less than \$0.1 million for the year ended ended December 30, 2021.

The Company has issued funding agreements to the FHLB of Des Moines in exchange for cash resulting in a liability of \$327.1 million as of September 30, 2022. The Company uses these funds in an investment spread strategy, consistent with its other investment spread operations. As such, the Company applies SSAP No. 52, *Deposit-Type Contracts*, accounting treatment to these funds, consistent with its other deposit-type contracts. It is not part of the Company's strategy to utilize these funds for operations, and any funds obtained from the FHLB of Des Moines for use in general operations would be accounted for consistent with SSAP No. 15 as borrowed money.

The Company must provide appropriate collateral to borrow under the arrangements described above. The borrowing capacity available to the Company under these agreements is largely a factor of the Company's ability to post eligible collateral, as well as internal limits such as single-holder exposure limits (10% of the entity's balance sheet liabilities) and NAIC capital requirements.

The tables below indicate the amount of FHLB of Des Moines stock purchased, collateral pledged, assets and liabilities related to the agreements with FHLB of Des Moines.

(2) FHLB capital stock

(a) Aggregate totals

	(1) Total (2+3)	(2) General Account	(3) Separate Accounts
1. Current Year			
(a) Membership stock - Class A	\$	\$	\$
(b) Membership stock - Class B	10,000,000	10,000,000
(c) Activity stock	13,600,000	13,600,000
(d) Excess stock
(e) Aggregate total (a+b+c+d)	<u>\$... 23,600,000</u>	<u>\$... 23,600,000</u>	<u>\$</u>
(f) Actual or estimated borrowing capacity as determined by the insurer	\$... 350,000,000		
2. Prior Year-End			
(a) Membership stock - Class A	\$	\$	\$
(b) Membership stock - Class B	10,000,000	10,000,000
(c) Activity stock	14,800,000	14,800,000
(d) Excess stock
(e) Aggregate total (a+b+c+d)	<u>\$... 24,800,000</u>	<u>\$... 24,800,000</u>	<u>\$</u>
(f) Actual or estimated borrowing capacity as determined by the insurer	\$... 500,000,000		

11B(2)a1(f) should be equal to or greater than 11B(4)a1(d)

11B(2)a2(f) should be equal to or greater than 11B(4)a2(d)

Notes to the Financial Statements

11. Debt (Continued)

(b) Membership stock (class A and B) eligible and not eligible for redemption

Membership Stock	(1) Current Year Total (2+3+4+5+6)	(2) Not Eligible for Redemption	Eligible for Redemption			
			(3) Less Than 6 Months	(4) 6 Months to Less Than 1 Year	(5) 1 to Less Than 3 Years	(6) 3 to 5 Years
1. Class A	\$	\$	\$	\$	\$	\$
2. Class B	\$ 10,000,000	\$ 10,000,000	\$	\$	\$	\$

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1)
 11B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

(3) Collateral pledged to FHLB

(a) Amount pledged as of reporting date

	(1)	(2)	(3)
	Fair Value	Carrying Value	Aggregate Total Borrowing
1. Current year total general and separate accounts total collateral pledged (Lines 2+3)	\$ 424,339,078	\$ 481,984,414	\$ 340,000,000
2. Current year general account total collateral pledged	424,339,078	481,984,414	340,000,000
3. Current year separate accounts total collateral pledged			
4. Prior year-end total general and separate accounts total collateral pledged	587,138,320	586,878,941	370,000,000

(b) Maximum amount pledged during reporting period

	(1)	(2)	(3)
	Fair Value	Carrying Value	Amount Borrowed at Time of Maximum Collateral
1. Current year total general and separate accounts maximum collateral pledged (Lines 2+3)	\$ 587,138,320	\$ 586,878,941	\$ 390,000,000
2. Current year general account maximum collateral pledged	587,138,320	586,878,941	390,000,000
3. Current year separate accounts maximum collateral pledged			
4. Prior year-end total general and separate accounts maximum collateral pledged	587,138,320	586,878,941	370,000,000

(4) Borrowing from FHLB

(a) Amount as of the reporting date

	(1)	(2)	(3)	(4)
	Total (2+3)	General Account	Separate Accounts	Funding Agreements Reserves Established
1. Current Year				
(a) Debt	\$	\$	\$	XXX
(b) Funding agreements	340,000,000	340,000,000		\$ 327,098,410
(c) Other				XXX
(d) Aggregate total (a+b+c)	<u>\$ 340,000,000</u>	<u>\$ 340,000,000</u>	<u>\$</u>	<u>\$ 327,098,410</u>
2. Prior Year-end				
(a) Debt	\$	\$	\$	XXX
(b) Funding agreements	370,000,000	370,000,000		\$ 355,041,450
(c) Other				XXX
(d) Aggregate total (a+b+c)	<u>\$ 370,000,000</u>	<u>\$ 370,000,000</u>	<u>\$</u>	<u>\$ 355,041,450</u>

(b) Maximum amount during reporting period (current year)

	(1) Total (2+3)	(2) General Account	(3) Separate Accounts
1. Debt	\$	\$	\$
2. Funding agreements	390,000,000	390,000,000	
3. Other			
4. Aggregate total (Lines 1+2+3)	<u>\$ 390,000,000</u>	<u>\$ 390,000,000</u>	<u>\$</u>

Notes to the Financial Statements

11. Debt (Continued)

(c) FHLB - Prepayment obligations

	Does the company have prepayment obligations under the following arrangements (YES/NO)?
1. Debt.....	NO.....
2. Funding agreements.....	NO.....
3. Other.....	NO.....

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans - None

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations - No Significant Changes

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

(1) Commitments or contingent commitment(s) to an SCA entity, joint venture, partnership, or limited liability company

As of September 30, 2022, the Company has unfunded commitments to invest in SCA entities, joint ventures, partnerships or limited liability companies of \$127.4 million.

As of September 30, 2022, the Company has unfunded commitments to invest in certain bonds and mortgage loans of \$1,409.6 million.

(2) Nature and circumstances of guarantee - No Significant Changes

(3) Aggregate compilation of guarantee obligations - No Significant Changes

B. Assessments - No Significant Changes

C. Gain Contingencies - None

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits - None

E. Joint and Several Liabilities - None

F. All Other Contingencies

Corporate-owned Life Insurance (COLI) Matter - In 2000 and 2001, two insurance companies which were subsequently merged into AAIA, purchased broad based variable COLI policies from American General Life Insurance Company (American General). In January 2012, the COLI policy administrator delivered to AAIA a supplement to the existing COLI policies and advised that American General and ZC Resource Investment Trust (ZC Trust) had unilaterally implemented changes set forth in the supplement that if effective, would: (1) potentially negatively impact the crediting rate for the policies and (2) change the exit and surrender protocols set forth in the policies. In March 2013, AAIA filed suit against American General, ZC Trust, and ZC Resource LLC in Chancery Court in Delaware, seeking, among other relief, a declaration that the changes set forth in the supplement were ineffectual and in breach of the parties' agreement. The parties filed cross motions for judgment as a matter of law, and the court granted defendants' motion and dismissed without prejudice on ripeness grounds. The issue that negatively impacts the crediting rate for one of the COLI policies has subsequently been triggered and on April 3, 2018, we filed suit against the same defendants in Chancery Court in Delaware seeking substantially similar relief. Defendants moved to dismiss and the court heard oral arguments on February 13, 2019. The court issued an opinion on July 31, 2019 that did not address the merits, but found that Chancery Court did not have jurisdiction over our claims and directed us to either amend our complaint or transfer the matter to Delaware Superior Court. The matter has been transferred to the Delaware Superior Court. Defendants renewed their motion to dismiss and the Superior Court heard oral arguments on December 18, 2019. The Superior Court issued an opinion on May 18, 2020 in which it granted in part and denied in part defendants' motion. The Superior Court denied defendants' motion with respect to the issue that negatively impacts the crediting rate for one of the COLI policies, which issue will proceed to discovery. The Superior Court granted defendants' motion and dismissed without prejudice on ripeness grounds claims related to the exit and surrender protocols set forth in the policies, and dismissed defendant ZC Resource LLC. If the supplement is ultimately deemed to be effective, the purported changes to the policies could impair AAIA's ability to access the value of guarantees associated with the policies. The parties engaged in discovery as well as discussions concerning whether the matter can be resolved without further litigation, and, at the request of the parties, on August 11, 2021, the court entered an Amended Scheduling Order setting the trial date for June 2023. On December 27, 2021, the parties agreed in principle to a settlement, pursuant to which we will be able to surrender the policies at any time and receive proceeds within six months. During the year ended December 31, 2021, AAIA recorded an impairment of the COLI asset of \$52.6 million, and an adjustment to deferred tax liabilities of \$46.9 million, to reflect the terms of the settlement.

Fiduciary or Best Interest Standards - The U.S. Securities and Exchange Commission (SEC), Department of Labor (DOL), NAIC, and several states have taken action or are exploring options around a fiduciary standard or best interest standard that may impact the Company and its subsidiaries. If these rules do not align, the distribution of products by the Company and its subsidiaries could be further complicated.

In 2019, the SEC adopted a rulemaking package designed to enhance the quality and transparency of retail investors' relationships with investment advisers and broker-dealers. The rulemaking package included: Regulation Best Interest - the Broker-Dealer Standard of Conduct; the new Form CRS Relationship Summary; and two separate interpretations under the Investment Advisers Act of 1940. The heightened requirements for broker-dealers and investment advisers apply to recommendations and sales of variable and other registered insurance and annuity products. The Company believes the Regulation and the interpretations of the Regulation may impact the distribution of its subsidiaries' products through third party broker-dealers that distribute the products to retail customers, the impact of which is still being determined.

The NAIC adopted the Suitability in Annuity Transactions Model Regulation (SAT), which places responsibilities upon issuing insurance companies with respect to the suitability of annuity sales, including responsibilities for training agents. On February 13, 2020, the SAT was amended to incorporate a "best interest" or similar standard with respect to the suitability of annuity sales. The amendments include a requirement for producers to act in the "best interest" of a consumer when making a recommendation of an annuity. A producer is considered to have acted in the best interest of the customer if they have satisfied certain prescribed obligations regarding care, disclosure, conflict of interest and documentation. State adoption of these revisions, and any future changes in such laws and regulations, may impact the way our US insurance subsidiaries market and sell their annuity products. Several states, including Iowa, have adopted or are in the process of adopting a version of the amended SAT that includes a best interest standard. On July 22, 2018, separate and apart from the NAIC, the NYDFS issued amendments to its SAT regulation to incorporate a "best interest" standard with respect to the suitability of life insurance and annuity sales. The amendments made by NYDFS are currently the subject of litigation. Other states, including California, could also adopt a "best interest" or other standard separate from the NAIC's SAT. Future changes in such laws and regulations, including those that impose a "best interest" standard, may impact the way the Company and its subsidiaries market and sell annuity products.

Notes to the Financial Statements

14. Liabilities, Contingencies and Assessments (Continued)

In April 2016, the DOL issued regulations expanding the definition of “investment advice” and broadening the circumstances under which distributors and manufacturers of insurance and annuity products could be considered “fiduciaries” and subject to certain standards in providing advice. These regulations were vacated effective June 2018. Thereafter, the DOL issued proposed regulatory action to address the vacated definition and to reinstate the pre-2016 regulatory definition of fiduciary advice on December 15, 2020. In the preamble to Prohibited Transaction Exemption (PTE) 2020-02, however, the DOL announced a new interpretation of parts of the regulation that broadens the circumstances under which producers, including insurance producers, could be considered fiduciaries under ERISA in connection with recommendations to “roll over” assets from a qualified retirement plan to an IRA or from an IRA to another IRA. For this purpose, “IRA” includes individual retirement annuities. This guidance reverses an earlier DOL interpretation suggesting that rollover advice by someone who was not already a fiduciary to a plan did not constitute investment advice giving rise to a fiduciary relationship. In connection with the broadened application of the fiduciary definition, the DOL’s PTE 2020-02 allows fiduciaries to receive compensation in connection with providing investment advice, including advice about rollovers, that would otherwise be prohibited as a result of their fiduciary relationship to the ERISA Plan, a participant in the ERISA Plan, or an IRA owner. The DOL has indicated they intend to issue further guidance or regulations with regards to these types of annuity sales. The Company and its subsidiaries continue to monitor the situation and will be reviewing whatever is issued to determine how it might apply to and impact our business.

In addition to the cases previously discussed, the Company is routinely involved in litigation and other proceedings, reinsurance claims and regulatory proceedings arising in the ordinary course of its business. At present, no other contingencies related to pending litigation and regulatory matters are considered material in relation to the financial position of the Company.

15. Leases - None

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk - No Significant Changes

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities - None

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans - None

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators - None

20. Fair Value Measurements

A. Fair Value Measurement

(1) Fair value measurements at reporting date

Description for each class of asset or liability	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds: Corporates	\$ -	\$ 5,082,586	\$ -	\$ -	\$ 5,082,586
Bonds: RMBS	-	525,888	2,602,303	-	3,128,191
Preferred stocks	-	310,432,206	5,246,894	-	315,679,100
Common stocks	-	23,600,000	-	-	23,600,000
Derivative assets: Currency Swaps	-	12,832,310	-	-	12,832,310
Derivative assets: Interest Rate	111,448	-	-	-	111,448
Derivative assets: Options	-	15,700,499	-	-	15,700,499
Derivative assets: Futures	1,269,150	-	-	-	1,269,150
Derivative assets: FX Forwards	-	255,350,349	-	-	255,350,349
Separate account assets: Variable products	-	12,992,180	-	-	12,992,180
Total assets at fair value/NAV	\$ 1,380,598	\$ 636,516,018	\$ 7,849,197	\$ -	\$ 645,745,813
b. Liabilities at fair value					
Derivative liabilities: Currency Swaps	\$ -	\$ 160,206,976	\$ -	\$ -	\$ 160,206,976
Derivative liabilities: Options	-	168,625	-	-	168,625
Derivative liabilities: Total Return Swaps	-	88,957	-	-	88,957
Derivative liabilities: FX Forwards	-	65,258,922	-	-	65,258,922
Separate account liabilities: Variable products	-	12,992,128	-	-	12,992,128
Total liabilities at fair value	\$ -	\$ 238,715,608	\$ -	\$ -	\$ 238,715,608

(2) Fair value measurements in Level 3 of the fair value hierarchy

Description	Beginning balance as of 07/01/2022	Transfers Into Level 3	Transfers Out of Level 3	Total Gains and (Losses) Included in Net Income	Total Gains and (Losses) Included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 09/30/2022
a. Assets										
Bonds: RMBS	\$ 2,791,878	\$ -	\$ -	\$ 12,060	\$ (190,555)	\$ -	\$ -	\$ -	\$ (11,080)	\$ 2,602,303
Preferred stocks	5,383,792	-	-	-	(136,898)	-	-	-	-	5,246,894
Common stocks	70,125	-	-	-	(70,125)	-	-	-	-	-
Total assets	\$ 8,245,795	\$ -	\$ -	\$ 12,060	\$ (397,578)	\$ -	\$ -	\$ -	\$ (11,080)	\$ 7,849,197
b. Liabilities										
Total liabilities	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

There were no transfers into or out of Level 3 of the fair value hierarchy during this quarter.

(3) Transfers between fair value hierarchy levels are recognized at the end of the period in which the transfer occurs.

(4) The following discussion describes the valuation methodologies and inputs used for assets and liabilities measured and disclosed at fair value. The techniques utilized in estimating the fair values of financial instruments are reliant on the assumptions used.

Notes to the Financial Statements

20. Fair Value Measurements (Continued)

Fair value estimates are based on quoted market prices when available. When quoted market prices are not available, the Company utilizes commercially available pricing vendors that utilize observable market inputs, like recent trading activity, to derive fair value. When vendor prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality (matrix pricing). In instances where there is little or no market activity for the same or similar instruments, the Company estimates the fair value using methods, models and assumptions that management believes market participants would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment which becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect risk inherent in a particular methodology, model or input employed.

The Company's financial assets and liabilities carried at estimated fair value have been classified, for disclosure purposes, based on a hierarchy defined by current accounting guidance. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The levels of the fair value hierarchy are as follows:

- Level 1 – Unadjusted quoted prices for identical assets or liabilities in an active market.
- Level 2 – Quoted prices for inactive markets or valuation techniques that require observable direct or indirect inputs for substantially the full term of the asset or liability.

Level 2 inputs include the following:

1. Quoted prices for similar assets or liabilities in active markets,
2. Observable inputs other than quoted market prices, and
3. Observable inputs derived principally from market data through correlation or other means.

- Level 3 – Prices or valuation techniques with unobservable inputs significant to the overall fair value estimate. These valuations use critical assumptions not readily available to market participants. Level 3 valuations are based on market standard valuation methodologies, including discounted cash flows, matrix pricing, or other similar techniques.

Asset and liabilities are valued as discussed below in part C.

(5) See parts (1) through (4) above.

B. Other Fair Value Disclosures - None

C. Fair Values for All Financial Instruments by Level 1, 2 and 3

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Assets - Bonds	\$ 19,701,619,492	\$ 22,697,142,235	\$ 21,278,488	\$ 16,958,975,608	\$ 2,721,365,396	\$	\$
Assets - Preferred stocks	315,679,100	315,757,895	—	310,432,206	5,246,894		
Assets - Common stock	23,600,000	23,600,000	—	23,600,000	—		
Assets - Mortgage loans - first liens	3,796,645,464	4,004,950,463	—	—	3,796,645,464		
Assets - Mortgage loans - other than first liens	270,615,015	288,803,711	—	—	270,615,015		
Assets - Cash and short-term investments	1,434,047,313	1,434,074,525	1,392,490,441	15,616,625	25,940,247		
Assets - Policy loans	2,064,185	2,064,185	—	2,064,185	—		
Assets - Derivative assets	441,356,163	403,683,081	(26,797,832)	468,153,995	—		
Assets - Derivative collateral assets	86,460,589	86,460,589	86,460,589	—	—		
Assets - Other invested assets	1,019,787,830	1,026,604,466	—	63,657,874	192,734,180	763,395,776	
Assets - Separate account: variable products	12,992,180	12,992,180	—	12,992,180	—		
Liabilities - Repurchase agreements	728,383,200	728,383,200	—	728,383,200	—		
Liabilities - Derivative liabilities	243,161,557	264,093,384	—	243,161,557	—		
Liabilities - Derivative and other collateral	300,252,000	300,252,000	300,252,000	—	—		
Liabilities - Deposit type contracts	390,653,234	398,098,869	—	390,653,234	—		

Bonds and short-term investments – The Company obtains the fair value for most marketable, public bonds without an active market from several commercial pricing services. These are classified as Level 2 assets. The pricing services incorporate a variety of market observable information in their valuation techniques, including benchmark yields, broker-dealer quotes, credit quality, issuer spreads, bids, offers, and other reference data. If the Company cannot value a public bond with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and is considered to be Level 3. The Company values privately placed bonds based on the credit quality and duration of comparable marketable securities, which may be securities of another issuer. In some instances, the Company uses a matrix-based pricing model. These models consider the current level of risk-free interest rates, corporate spreads, credit quality of the issuer, and cash flow characteristics of the security. Privately placed fixed maturity securities are classified as Level 2 or 3.

Preferred stocks and common stocks unaffiliated – The Company values equity securities, typically private equities or equity securities not traded on an exchange, using several commercial pricing services or an internal model. The securities priced by a commercial pricing service are classified as Level 2 and the securities priced by an internal model are classified as Level 3. In addition, unaffiliated common stocks include FHLB stock, which is carried at fair value, which is presumed to be par because it can only be redeemed by the bank and is classified as Level 2.

Mortgage loans – The Company estimates mortgage loans on a monthly basis using discounted cash flow analysis and rates being offered for similar loans to borrowers with similar credit ratings. Loans with similar characteristics are aggregated for purposes of the calculations. The discounted cash flow model uses unobservable inputs, including estimates of discount rates and loan prepayments. Mortgage loans are classified as Level 3.

Policy loans – The fair value of policy loans classified as Level 2 is equal to the carrying value of the loans, which are collateralized by the cash surrender value of the associated insurance contracts.

Notes to the Financial Statements

20. Fair Value Measurements (Continued)

Derivatives – Derivative contracts can be exchange traded or over-the-counter. Over-the-counter derivatives are valued using valuation models or an income approach using third-party broker valuations. Valuation models require a variety of inputs, including contractual terms, market prices, yield curves, credit curves, measures of volatility, prepayment rates, and correlation of the inputs. The Company considers and incorporates counterparty credit risk in the valuation process through counterparty credit rating requirements and monitoring of overall exposure. The Company also evaluates and includes its own nonperformance risk in valuing derivatives. The majority of the Company's derivatives trade are in liquid markets; therefore, the Company can verify model inputs and model selection does not involve significant management judgment and are classified within Level 2. If the Company cannot verify model inputs and model selection does involve significant management judgment, the derivatives are classified as Level 3.

Other invested assets – Within other invested assets, partnerships are valued based on net asset value information provided by the general partner or related asset manager. These partnership interests usually include multiple underlying investments for which either observable market prices or other valuation methods are used to determine the fair value. These investments are reported in the Net Asset Value (NAV) column. Other than partnerships, other invested assets may include surplus notes and other investments with bond or stock characteristics and the Company attempts to value these using commercial pricing services, which would be classified as Level 2 assets. If the Company cannot value with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3 assets.

Separate account assets (variable products) – Separate account assets classified as Level 2 are valued based on the fair value of the underlying funds. Fair values and changes in the fair values of separate account assets accrue directly to the policyowners and are not included in the Company's revenues and expenses or surplus.

Repurchase agreements - The carrying value of the repurchase agreements liability approximates fair value and is reported as level 2.

Deposit-type contracts – Deposit-type contracts are classified as Level 3 include single premium immediate annuities (SPIA), supplemental contracts, and group pension contracts. Fair value of SPIA, supplemental contracts, and group pension are calculated by discounting best estimate cash flows based on market interest rate assumptions.

D. Not Practicable to Estimate Fair Value - None

E. Nature and Risk of Investments Reported at NAV

The Company invests in certain non-fixed income, alternative investments in the form of limited partnerships (investment funds) which are reported at net asset value (NAV). Adjustments to the carrying amount reflect the Company's pro rata ownership percentage of the operating results as indicated by NAV in the investment fund financial statements. The NAV from the investment fund financial statements can be on a lag of up to three months when investee information is not received in a timely manner. These investments are listed in the NAV column of the fair value tables above as this is the primary method for reporting fair value for these investments.

As of September 30, 2022, the Company has \$127.4 million unfunded commitments to invest in these investment funds.

21. Other Items - No Significant Changes

22. Events Subsequent

Subsequent events have been considered through November 14, 2022 for the statutory statement dated September 30, 2022.

23. Reinsurance

The Company entered into a coinsurance agreement on January 1, 2018 with AAIA, pursuant to which it assumes from AAIA a 50% quota share of certain annuity business issued between January 1, 2018 and December 31, 2021. The Company has recognized a reserve of \$13,804.1 million as of December 31, 2021 for this block. Effective January 1, 2022, AAIA recaptured the payout annuities ceded to the Company under this reinsurance agreement. Coinsurance reserves for the payout annuities recaptured by AAIA were \$135.4 million as of January 1, 2022.

A. Ceded Reinsurance Report - No Significant Changes

B. Uncollectible Reinsurance - None

C. Commutation of Reinsurance Reflected in Income and Expenses - None

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation - None

E. Reinsurance of Variable Annuity Contracts with an Affiliated Captive Reinsurer - None

F. Reinsurance Agreement with an Affiliated Captive Reinsurer - None

G. Ceding Entities That Utilize Captive Reinsurers to Assume Reserves Subject to the XXX/AXXX Captive Framework - None

H. Reinsurance Credit - None

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate - Not Applicable

B. Method Used to Record - Not Applicable

C. Amount and Percent of Net Retrospective Premiums - Not Applicable

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act - Not Applicable

E. Risk-Sharing Provisions of the Affordable Care Act (ACA)

(1) Accident and health insurance premium subject to the Affordable Care Act risk-sharing provisions

Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions?

No

(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year - Not Applicable

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance - Not Applicable

Notes to the Financial Statements

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

(4) Roll-forward of risk corridors asset and liability balances by program benefit year - Not Applicable

(5) ACA risk corridors receivable as of reporting date - Not Applicable

25. Change in Incurred Losses and Loss Adjustment Expenses - None

26. Intercompany Pooling Arrangements - None

27. Structured Settlements - None

28. Health Care Receivables - None

29. Participating Policies - No Significant Changes

30. Premium Deficiency Reserves - None

31. Reserves for Life Contracts and Annuity Contracts - No Significant Changes

32. Analysis of Annuity Actuarial Reserves and Deposit Type Contract Liabilities by Withdrawal Characteristics - No Significant Changes

33. Analysis of Life Actuarial Reserves by Withdrawal Characteristics - No Significant Changes

34. Premiums and Annuity Considerations Deferred and Uncollected - None

35. Separate Accounts - No Significant Changes

36. Loss/Claim Adjustment Expenses - None